natgillin/translations-raw huggingface dataset:
The CHMP recommends that the terms of the Marketing Authorisation should be varied.
Odbor CHMP zato priporoča spremembo pogojev dovoljenja (dovoljenj) za promet z zdravilom.
The most frequently reported adverse reactions during the Xiapex clinical studies (272 of 409 patients received up to three single injections of Xiapex and 775 patients received two concurrent injections in the same hand) were local injection site reactions such as oedema peripheral (local to the injection site), contusion (including ecchymosis), injection site haemorrhage and injection site pain.
Najpogosteje poročani neželeni učinki med kliničnimi študijami zdravila Xiapex (do tri enkratne injekcije zdravila Xiapex je prejelo 272 od 409 bolnikov in 775 bolnikov je prejelo dve sočasni injekciji v isto roko) so bili: reakcije na mestu aplikacije, kot na primer periferni edem (na mestu injiciranja), kontuzija (vključno z ekhimozo), krvavitev na mestu injiciranja in bolečina na mestu injiciranja.
If, at that subsequent visit the contracted cord persists, an additional injection and finger extension procedure may be performed.
Če je kontrakturni vozlič na tem naknadnem obisku še prisoten, se lahko opravi dodatni postopek injiciranja in iztegovanja prstov.
In contrast, the Class II collagenases (δ, ε, and ζ,) are products of colH gene, their initial cleavage sites are located within the interior of the collagen molecule and generate smaller collagen fragments.
Nasprotno pa so kolagenaze razreda II (δ, ε, in ζ,) produkti gena colH, njihova cepilna mesta se nahajajo znotraj kolagenske molekule in proizvajajo manjše kolagenske fragmente.
Tell your doctor if you have previously received or are thinking about receiving Xiapex to treat a condition known as Peyronie's disease.
Zdravniku povejte, če ste že prejemali ali razmišljate o prejemanju zdravila Xiapex za zdravljenje bolezni, imenovane Peyroniejeva bolezen.
See Figure 1 below for an illustration of the injection technique.
spodaj za prikaz tehnike injiciranja.
Injection of Xiapex into a Dupuytren's cord, which is comprised mostly of interstitial collagen types I and III, results in enzymatic disruption of the cord.
Injiciranje zdravila Xiapex v Dupuytrenov vozlič, ki je večinoma sestavljen iz intersticijskega kolagena tipa I in III, povzroči encimsko prekinitev vozliča.
The goal is to gradually create bending opposite to the patient's penile curvature, with stretching to the point of moderate resistance.
Cilj je, da se z raztezanjem do točke zmernega odpora postopno ustvari upognjenost, ki je nasprotna bolnikovi ukrivljenosti penisa.
The vial containing the solution should not be inverted or shaken.
Viale, ki vsebuje raztopino, ne smete obračati ali tresti.
At baseline, the mean (SD) Female PDQ score was 4.7 (3.61) and 2.7 (3.06) at week 36, i.e. a change from baseline of -2.0.
Ob izhodišču je bil povprečni (SD) seštevek PDQ za ženske 4,7 (3,61), v 36. tednu pa 2,7 (3,06), tj. sprememba od izhodišča za -2,0.
The volume of reconstituted Xiapex to be administered into the plaque is 0.25 ml (for reconstitution instructions, see section 6.6, Table 14).
Volumen rekonstituiranega zdravila Xiapex, ki ga bomo dali v plak, je 0,25 ml (za navodila glede rekonstitucije glejte poglavje 6.6, preglednico 14).
Class I cleaves insoluble triple helical collagen with higher affinity than Class II collagenase.
Razred I cepi netopno trojno spiralo kolagena z večjo afiniteto kot kolagenaze razreda II.
Do not have sex or have any other sexual activity for at least 4 weeks after the second injection of a treatment cycle with Xiapex and after any pain and swelling has ceased and be cautious when resuming sexual activity.
Spolnega odnosa ali drugih spolnih aktivnosti ne smete imeti vsaj 4 tedne po drugi injekciji v ciklu zdravljenja z zdravilom Xiapex in po izginotju vsakršne bolečine in otekline ter bodite previdni, ko postanete ponovno spolno aktivni.
(degrees)
(stopinje)
0.25 ml †Note that injection volume for delivery of a 0.58 mg dose is less than the total volume of solvent used for reconstitution.
0,25 ml †Volumen injekcije za prenos odmerka 0,58 mg je manjši kot skupni volumen vehikla, uporabljenega za rekonstitucijo.
Most patients experiencing tendon/ligament rupture or injury have gone on to have successful surgical repair.
Pri večini bolnikov so rupturo kite/ligamenta ali poškodbo uspešno kirurško zdravili.
The majority of adverse events reported during the long-term follow-up period were non-serious, mild or moderate in intensity, and were not related to the local administration of Xiapex.
Večina neželenih učinkov, o katerih so poročali v dolgoročnem obdobju spremljanja, ni bilo resnih in so bili po intenzivnosti blagi ali zmerni ter nepovezani z lokalnim apliciranjem zdravila Xiapex.
Physician-rated change in contracture severity was reported as very much improved or much improved in 86% and 80% of the subjects in the Xiapex group compared to 3% and 5% of subjects in the placebo group for the CORD I and CORD II studies, respectively (p<0.001).
Zdravnikova ocena spremembe resnosti kontrakture je bila poročana kot zelo izboljšano stanje ali precej izboljšano stanje v 86 % in 80 % preskušancev v skupini z zdravilom Xiapex v primerjavi s 3 % in 5 % preskušancev v skupini placebo za študiji CORD I in CORD II (p < 0,001).
If the first finger extension procedure does not result in disruption of the cord, a second and third attempt can be performed at 5- to 10-minute intervals.
Če po prvem postopku iztegovanja prstov ne pride do prekinitve vozliča, se lahko v 5 do 10-minutnih intervalih postopek ponovi še drugič ali tretjič.
The double-blind study population comprised 832 male patients of whom 551 patients received Xiapex and 281 received placebo.
Populacijo dvojno slepe študije je sestavljalo 832 moških bolnikov, od katerih je 551 bolnikov prejemalo zdravilo Xiapex in 281 jih je prejemalo placebo.
A. MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE AND MANUFACTURER(S) RESPONSIBLE FOR BATCH RELEASE
A. IZDELOVALEC (IZDELOVALCI) BIOLOŠKE UČINKOVINE IN IZDELOVALEC (IZDELOVALCI), ODGOVOREN (ODGOVORNI) ZA SPROŠČANJE SERIJ
• The treatment of Dupuytren's contracture in adult patients with a palpable cord.
• zdravljenje Dupuytrenove kontrakture pri odraslih bolnikih z otipljivim vozličem.
Solvent required for reconstitution
Vehikel, potreben za rekonstitucijo
The second Xiapex injection is administered 1 to 3 days after the first injection.
Druga injekcija zdravila Xiapex se injicira 1 do 3 dni po prvi injekciji.
• Proper amount of volumes for both reconstitution and injection differences in the metocarpophalangeal (MP) and proximal interphalangeal (PIP) joints for Dupuytren's contracture and for the Peyronie's disease plaque.
• ustrezne količine rekonstitucijske tekočine in tekočine za injiciranje, ki so različne za metakarpofalangealne (MP) in proksimalne interfalagealne (PIP) sklepe, za Dupuytrenovo kontrakturo in plak Peyroniejeve bolezni,
When administering two injections in the same hand during a treatment visit, use a new syringe and separate vial of reconstituted solution (containing 0.58 mg of Xiapex) for the second injection.
Pri dajanju dveh injekcij v isto roko med obiskom za zdravljenje je treba uporabiti novo injekcijsko brizgo in ločeno vialo z rekonstituirano raztopino (ki vsebuje 0,58 mg zdravila
If the needle is in the proper location, there will be some resistance noted during the injection procedure.
Če je igla na pravilnem mestu, boste med injiciranjem čutili malo upora.
Care should be taken when injecting Xiapex into cords contracting the PIP joints as clinical studies indicate an increased risk of tendon rupture and ligament injury associated with treatment of PIP contractures with Xiapex.
Previdnost je potrebna pri injiciranju zdravila Xiapex v kontrakcijske vozliče PIP sklepov, saj klinične študije kažejo povečano tveganje rupture kite in poškodbe ligamenta, povezane z zdravljenjem kontraktur PIP sklepov z zdravilom Xiapex.
Again keeping the needle under the skin at all times, withdraw the needle tip from the cord and reposition it a third time proximal to the initial injection (approximately 2-3 mm) and inject the final portion of the dose into the cord (see Figure 2).
Ponovno pazite, da je igla ves čas pod kožo, in ponovno izvlecite konico igle iz vozliča ter jo namestite proksimalno od prvotnega mesta injiciranja (približno 2 do 3 mm) in injicirajte še zadnjo tretjino odmerka v vozlič (glejte sliko 2).
A penile modelling procedure is performed 1 to 3 days after the second injection of each treatment cycle.
Postopek modeliranja penisa se opravi 1 do 3 dni po drugi injekciji vsakega cikla zdravljenja.
The study inclusion and exclusion criteria as well as the treatment schedule and the co-primary efficacy endpoints were the same as in the pivotal AUX-CC-803 and AUX-CC-804 studies.
Vključitvena in izključitvena merila za študijo, pa tudi režim zdravljenja ter sočasni primarni opazovani dogodki, so bili enaki kot v ključnih študijah AUX-CC-803 in AUX-CC-804.
• Perform a series of finger flexion and extension exercises several times a day for several months.
• naj izvajajo serije vaj upogibanja in iztegovanja prstov večkrat dnevno več mesecev.
Xiapex must be reconstituted with the solvent provided and to the appropriate volume prior to intralesional injection (see section 6.6).
Zdravilo Xiapex je treba pred intralezijsko injekcijo rekonstituirati do primernega volumna z vehiklom, ki je priložen (glejte poglavje 6.6).
Xiapex must only be injected into the Dupuytren's cord.
Zdravilo Xiapex je treba injicirati samo v Dupuytrenov vozlič.
Peyronie's disease occurs exclusively in adult male patients and hence there is no relevant use of Xiapex in the paediatric population aged 0-18 years for the treatment of Peyronie's disease.
Peyroniejeva bolezen se pojavlja samo pri odraslih moških bolnikih, zato zdravilo Xiapex ni primerno za uporabo pri pediatrični populaciji, stari od 0-18 let, za zdravljenje Peyroniejeve bolezni.
The incidence of Xiapex-associated pruritus was similar after each injection regardless of the number of injections administered.
Incidenca pruritusa, povezanega z zdravilom Xiapex, je bila po vsaki injekciji podobna, ne glede na število danih injekcij.
During clinical studies, blood samples from patients with Dupuytren's contracture and Peyronie's disease were tested at multiple time points for antibodies to the protein components of the medicinal product (AUX-I and AUX-II).
Med kliničnimi študijami so večkrat testirali krvne vzorce bolnikov z Dupuytrenovo kontrakturo in Peyroniejevo boleznijo na prisotnost protiteles proti beljakovinskim komponentam zdravila (AUX-I in AUX-II).
Recurrence was assessed in successfully treated joints (i.e., subjects had a reduction in contracture to 5° or less at the Day 30 evaluation after the last injection of Xiapex in a previous study) and was defined as an increase in joint contracture by at least 20° in the presence of a palpable cord, or the joint underwent medical or surgical intervention primarily to correct a new or worsening Dupuytren's contracture in that joint.
Ponovitev je bila ocenjevana v uspešno zdravljenih sklepih (tj. osebe so imele zmanjšanje kontrakture na 5° ali manj na 30. dan ocenitve po zadnji injekciji zdravila Xiapex v predhodni študiji) in je bila definirana kot zvečanje kontrakture sklepa na vsaj 20° v prisotnosti otipljivega vozliča, ali pa je bil na sklepu opravljen zdravniški ali operativni poseg, primarno za korekturo nove ali poslabšane
Table 1 presents adverse reactions listed by system organ class and frequency categories, using the following convention: very common (≥1/10), common (≥1/100 to <1/10), and uncommon (≥1/1,000 to <1/100), and not known: cannot be estimated from the available data.
V preglednici 2 so predstavljeni neželeni učinki, našteti po organskih sistemih in kategorijah pogostnosti po naslednjem dogovoru: zelo pogosti (≥ 1/10), pogosti (≥ 1/100 do < 1/10), občasni (≥ 1/1.000 do < 1/100) in neznana pogostnost: ni mogoče oceniti iz razpoložljivih podatkov.
c) Administer suitable local anaesthetic, if desired.
c) Po želji uporabite ustrezni lokalni anestetik.
If cords of two affected joints in one finger were treated, perform the finger extension procedure on the cord affecting the MP joint before performing the procedure on the cord affecting the PIP joint.
Če zdravite vozliča dveh prizadetih sklepov enega prsta, izvedite postopek iztegovanja prstov na vozliču, ki je prizadel MP sklep, preden postopek izvedete na vozliču, ki je prizadel PIP sklep.
Injection of Xiapex into a Peyronie's plaque, which is comprised mostly of collagen, may result in enzymatic disruption of the plaque.
Injiciranje zdravila Xiapex v Peyroniejev plak, ki je večinoma sestavljen iz kolagena, lahko povzroči encimsko prekinitev plaka.
• abnormal sensation
• nenormalen občutek
The solvent that is used to dissolve the powder is a clear colourless liquid.
Vehikel, ki se uporablja za raztapljanje praška, je prosojna brezbarvna tekočina.
Corporal rupture was reported as a serious adverse reaction after Xiapex injection in 5 out of 1044 patients (0.5%) in the controlled and uncontrolled clinical trials in Peyronie's disease.
O rupturi korpusa so poročali kot o resnem neželenem učinku po injiciranju zdravila Xiapex pri 5 od 1.044 bolnikov (0,5 %) v nadzorovanih in nenadzorovanih kliničnih preskušanjih pri Peyroniejevi bolezni.
With the other hand, hold the base of your penis with the fingers (see Figure 3).
S prsti druge roke držite koren penisa (glejte sliko 3).
In the Peyronie's disease clinical studies, at 6 weeks after the first treatment cycle of Xiapex, approximately 75% of patients had antibodies against AUX-I and approximately 55% of patients had antibodies against AUX-II.
V kliničnih študijah Peyroniejeve bolezni je imelo 6 tednov po prvem ciklu zdravljenja z zdravilom Xiapex približno 75 % bolnikov protitelesa proti AUX-I in približno 55 % bolnikov je imelo protitelesa proti AUX-II.
Withdraw the needle slowly so as to deposit the full dose along the needle track within the plaque.
Iglo počasi izvlecite tako, da celoten odmerek vnašate vzdolž poti igle znotraj plaka.
The reduction in the Bother domain score was numerically similar between patient groups stratified by degree of baseline curvature deformity (30 to 60 degrees and 61 to 90 degrees).
Zmanjšanje rezultata Področja težav je bilo v številkah podobno med skupinama bolnikov, stratificiranima po stopnji deformacije ukrivljenosti ob izhodišču (30 do 60 stopinj in 61 do 90 stopinj).
• The other ingredients are sucrose, trometamol and hydrochloric acid 2.4% w/w (for pH
• Pomožne snovi so saharoza, trometamol in klorovodikova kislina 2,4 % w/w (za uravnavanje pH).
Improvement of the total fixed flexion contracture was also observed irrespectively of the time of finger extension, 24, 48 or 72 hours after injection, with a mean improvement at Day 31 of 75.2% 74.8% and 72.4% respectively.
24, 48 oz. 72 ur po injekciji, s povprečnim izboljšanjem 31. dne za 75,2 %, 74,8 % oz. 72,4 %.
In the unlikely event that your doctor administers a higher dose than recommended, you may experience an increase in the severity of possible side effects listed in section 4 “Possible Side Effects”.
Če vam bo zdravnik kljub majhni verjetnosti dal večji odmerek od priporočenega, se utegnejo pojaviti resnejši neželeni učinki, ki so navedeni v poglavju 4 »Možni neželeni učinki« tega navodila za uporabo.
Neutralizing antibodies to AUX-I or AUX-II, were detected in 60% and 51.8%, respectively, of patients tested.
Nevtralizirajoča protitelesa proti AUX-I so odkrili pri 60 % , proti AUX-II pa pri 51,8 % testiranih bolnikov.
The target plaque is used as a fulcrum point with both hands, to firmly apply a steady pressure to elongate and stretch the plaque.
Ciljni plak služi kot vzvodna točka, na katero se z obema rokama izvaja čvrst stalen pritisk in s tem podaljšuje in razteza plak.
In addition, patients were instructed to perform penile modelling at home for six weeks after each treatment cycle.
Poleg tega so bolnikom naročili, naj šest tednov po vsakem ciklu zdravljenja doma izvajajo modeliranje penisa.
If the solution contains particulates, is cloudy, or is discoloured, do not inject the reconstituted solution.
Če raztopina vsebuje delce, je motna ali obarvana, ne injicirajte rekonstituirane raztopine.
In each treatment cycle, two injections of Xiapex 0.58 mg or two injections of placebo were administered 1 to 3 days apart.
V vsakem ciklu zdravljenja so bolniki dobili dve injekciji zdravila Xiapex 0,58 mg ali dve injekciji placeba z razmikom 1 do 3 dni.
In a single-dose phase or 61-day repeat-dose phase (3 times a week every 3 weeks for 3 cycles) study of intrapenile administration of collagenase clostridium histolyticum in dogs at exposures lower than or equal to the maximum recommended human dose on a mg/m2 basis, there was no evidence of systemic toxicity.
V študiji intrapenilnega dajanja kolagenaze clostridium histolyticum psom v fazi enega odmerka ali v fazi 61-dnevnega ponavljajočega odmerjanja (3 cikli po 3-krat na teden vsake 3 tedne) pri izpostavljenostih, nižjih ali enakih največjemu priporočenemu odmerku pri ljudeh na podlagi mg/m2, ni bilo znakov sistemske toksičnosti.
• 0.39 ml of solvent for the penile plaque in Peyronie's disease e) Inject the diluent slowly into the sides of the vial containing the lyophilized powder of Xiapex.
• 0,39 ml vehikla za plak penisa pri Peyroniejevi bolezni e) Vehikel počasi injicirajte ob steno viale, ki vsebuje liofiliziran prašek zdravila Xiapex.
For joints reported as recurring in a previous study, the day of recurrence was the first visit with a fixed flexion contracture measurement of 20° or greater following the report of recurrence.
Za sklepe, pri katerih je bila ponovitev poročana v prejšnji študiji, je bil dan ponovitve prvi obisk s popravljeno izmerjeno fleksijsko kontrakturo
The diluent contains calcium which is required for the activity of Xiapex.
Vehikel vsebuje kalcij, ki je potreben za delovanje zdravila Xiapex.
A study AUX-CC-862 was conducted in patients with Dupuytren's contracture who had recurrence of contracture in a joint that was effectively treated with Xiapex in a previous clinical study.
Študijo AUX-CC-862 so izvedli pri bolnikih z Dupuytrenovo kontrakturo, ki se jim je kontraktura ponovila v sklepu, ki je bil v predhodni klinični študiji učinkovito zdravljen z zdravilom Xiapex.
Diagnostic imaging is recommended after manipulation if finger deformity, pain or increased swelling develops (see also section 4.8).
Če se po obravnavi razvije deformacija prsta, bolečina ali povečana oteklina, se priporoča diagnostično slikanje (glejte tudi poglavje 4.8).
Xiapex is comprised of a mixture of Class I (AUX-I) and Class II (AUX-II) clostridial collagenases in a defined mass ratio.
Zdravilo Xiapex sestavlja mešanica razreda I (AUX-I) in razreda II (AUX-II) klostridijskih kolagenaz v določenem masnem razmerju.
If your cord to be treated is attached to the skin, you are at higher risk of the skin splitting or tearing during the finger extension procedure following the injection of Xiapex.
Če je vozlič, ki vam ga bodo zdravili, pričvrščen na kožo, obstaja večje tveganje, da bo prišlo do prebodenja ali raztrganja kože med postopkom iztegovanja prstov, ki sledi injiciranju zdravila Xiapex.
Call your doctor right away if you experience any of the symptoms of penile fracture or serious injury to your penis listed above, as this may require surgical intervention.
Takoj pokličite zdravnika, če se pojavijo kateri koli simptomi zloma penisa ali resne poškodbe penisa, naštete zgoraj, saj bi bil zaradi tega morda lahko potreben kirurški poseg.
A penile modelling procedure was performed on patients at the study site 1 to 3 days after the second injection of the cycle.
Postopek modeliranja penisa je bil opravljen pri bolnikih na mestu poteka študije 1 do 3 dni po drugem injiciranju v ciklu.
Elevate the injected hand as much as possible until the day after the finger extension procedure.
Zdravljeno roko držite dvignjeno, kolikor je možno, do dneva po postopku iztegovanja prstov.
For each subject in whom a Week 12 sample was selected, the corresponding Week 6, 18, 24, and 52 samples were assayed if they were also binding antibody positive.
Za vsako osebo, za katero je bil izbran vzorec iz 12. tedna, so bili testirani tudi ustrezni vzorci iz 6., 18., 24. in
Tables 11-12 provide the results of the co-primary efficacy endpoints measured in the open label phase 3 study AUX-CC-806.
V preglednicah 11-12 so rezultati sočasnih primarnih opazovanih dogodkov učinkovitosti, izmerjenih v odprti študiji 3. faze, AUX-CC-806.
Receiving an injection of Xiapex may cause damage to the tubes in your penis called the corpora.
Injiciranje zdravila Xiapex lahko poškoduje cevke v penisu, imenovane korpusi.
Absorption Following administration of either a single dose of 0.58 mg of Xiapex to 16 patients with Dupuytren's contracture, or two concurrent injections of 0.58 mg of Xiapex in the same hand in 12 patients with Dupuytren's contracture, no quantifiable levels of Xiapex were detected in plasma from 5 minutes to 30 days post injection.
Absorpcija Po aplikaciji bodisi enkratnega odmerka 0,58 mg zdravila Xiapex 16 bolnikom z Dupuytrenovo kontrakturo ali dveh sočasnih injekcij po 0,58 mg zdravila Xiapex v isto roko 12 bolnikom z Dupuytrenovo kontrakturo v času od 5 minut do 30 dni po injiciranju ni bilo zaznati merljivih nivojev zdravila Xiapex v plazmi.
• After a 30 second rest period, repeat the penile modelling technique for a total of 3 modelling attempts at 30 seconds for each attempt.
• Nato ga sprostite in počakajte 30 sekund, preden tehniko modeliranja penisa ponovite, in sicer skupaj izvedite 3 poskuse s po 30 sekundami za vsak poskus.
Baseline disease characteristics of patientsa with Peyronie's Disease (PD)
Značilnosti bolezni ob izhodišču pri bolnikiha s Peyroniejevo boleznijo (PB)
This is a condition where adult men have a ‘plaque' that can be felt and a curve to their penis.
To je bolezen, pri kateri imajo odrasli moški ‘plak', ki se ga lahko otipa, in ukrivljenost penisa.
• 0.25 ml of reconstituted Xiapex for cords affecting a MP joint or • 0.20 ml of reconstituted Xiapex for cords affecting a PIP joint.
• 0,25 ml rekonstituiranega zdravila Xiapex za vozliče, ki prizadenejo MP sklep, ali • 0,20 ml rekonstituiranega zdravila Xiapex za vozliče, ki prizadenejo PIP sklep.
The overall safety profile was similar in the two Phase 3 double-blind placebo-controlled studies (832 male patients, 551 patients received Xiapex) and in an open-label Phase 3 study (189 male patients) of patients who had previously received placebo in the controlled studies.
Splošni varnostni profil je bil podoben v dveh dvojno slepih, s placebom nadzorovanih študijah 3. faze (832 bolnikov moškega spola, 551 bolnikov je prejemalo zdravilo Xiapex) in v odprti študiji 3. faze (189 bolnikov moškega spola) pri bolnikih, ki so predhodno v nadzorovanih študijah prejemali placebo.
Severe penile haematoma was also reported as an adverse reaction in 39 of 1044 patients (3.7%) in the controlled and uncontrolled clinical studies in Peyronie's disease.
O hudem hematomu penisa kot neželenem učinku so poročali pri 39 od 1.044 bolnikov (3,7 %) v nadzorovanih in nenadzorovanih kliničnih študijah pri Peyroniejevi bolezni.
Xiapex also demonstrated a clinically significant benefit compared to placebo in decreasing the degree of contracture and increasing both the range of motion from baseline for all joints treated (MP plus PIP, MP only, PIP only) and the subject global assessment of treatment satisfaction.
Zdravilo Xiapex je pokazalo tudi klinično pomembne koristi v primerjavi s placebom pri zmanjšanju stopnje kontrakture in zvečanju razpona gibanja glede na izhodišče za vse zdravljene sklepe (MP in PIP, samo MP, samo PIP), kot tudi pri globalni oceni zadovoljnosti z zdravljenjem preskušanca.
The syringe and needle used for reconstitution are thereafter removed and discarded.
Brizgo in iglo, ki ste ju uporabili za rekonstitucijo, potem odstranite in zavrzite.